Showing results (921-930 of 3,017) with videos related to

Sort By:
Pageof 302
Journal of Cardiac Failure|May 14, 2013
Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarctionJames D Richardson, Angela G Bertaso, Peter J Psaltis, et al.
Journal of Cardiac Failure|June 8, 2013
Acute decompensated heart failure: update on new and emerging evidence and directions for future researchMichael M Givertz, John R Teerlink, Nancy M Albert, et al.
Journal of Cardiac Failure|June 8, 2013
Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fractionNiyada Naksuk, Ali Saab, Jian-Ming Li, et al.
Journal of Cardiac Failure|May 29, 2012
Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HFDavid J Whellan, Margueritte Cox, Adrian F Hernandez, et al.
Journal of Cardiac Failure|December 20, 2005
Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trialJ Jamie Caro, Kristin Migliaccio-Walle, Judith A O'Brien, et al.
Journal of Cardiac Failure|December 20, 2005
The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failureMatthew J Kolek, John F Carlquist, Surai Thaneemit-Chen, et al.
Journal of Cardiac Failure|December 20, 2005
The utility of microvascular perfusion assessment in heart failure: a pilot studyChristopher J Hogan, Michael L Hess, Kevin R Ward, et al.
Journal of Cardiac Failure|June 1, 1997
Removal from the "waiting list" for heart transplantation: a risk factor for sudden death?C V Leier, G Whitby, R A Kennedy, et al.
Journal of Cardiac Failure|December 1, 2009
Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluationMark E Patterson, William C Grant, Seth W Glickman, et al.
Pageof 302